Cardiology - Medtelligence

1-16 of 136

Engaging Patients With Heart Failure and Chronic Hyperkalemia: Shared Decision-Making to Support Guideline-Directed Medical Therapy
Engaging Patients With Heart Failure and Chronic Hyperkalemia: Shared Decision-Making to Support Guideline-Directed Medical Therapy
CME/CE
Engaging Patients With Heart Failure and Chronic Hyperkalemia: Shared Decision-Making to Support Guideline-Directed Medical Therapy
Gianluigi Savarese, MD, PhD, FESC, FHFA
0.25 credits
- Gianluigi Savarese, MD, PhD, FESC, FHFA
0.25 credits
Extra Innings – Sustaining Victory Beyond the First Game
Extra Innings – Sustaining Victory Beyond the First Game
MinuteCE®
Extra Innings – Sustaining Victory Beyond the First Game
J.A. Randy Englert, MD, FACC; Matthew Malachowski, Pharm. D., MHA
0.75 program credits
- J.A. Randy Englert, MD, FACC
- Matthew Malachowski, Pharm. D., MHA
0.75 program credits
Turning the Double Play – Comprehensive Secondary Prevention
Turning the Double Play – Comprehensive Secondary Prevention
MinuteCE®
Turning the Double Play – Comprehensive Secondary Prevention
J.A. Randy Englert, MD, FACC; Matthew Malachowski, Pharm. D., MHA
0.75 program credits
- J.A. Randy Englert, MD, FACC
- Matthew Malachowski, Pharm. D., MHA
0.75 program credits
Leadoff Hitter – Spotting High-Risk Players
Leadoff Hitter – Spotting High-Risk Players
MinuteCE®
Leadoff Hitter – Spotting High-Risk Players
J.A. Randy Englert, MD, FACC
0.75 program credits
- J.A. Randy Englert, MD, FACC
0.75 program credits
Small Ball Wins Games – Combination Therapy for Goal Attainment
Small Ball Wins Games – Combination Therapy for Goal Attainment
MinuteCE®
Small Ball Wins Games – Combination Therapy for Goal Attainment
J.A. Randy Englert, MD, FACC; Matthew Malachowski, Pharm. D., MHA
0.75 program credits
- J.A. Randy Englert, MD, FACC
- Matthew Malachowski, Pharm. D., MHA
0.75 program credits
Swing for the Fences – LDL-C as the Power Hitter
Swing for the Fences – LDL-C as the Power Hitter
MinuteCE®
Swing for the Fences – LDL-C as the Power Hitter
J.A. Randy Englert, MD, FACC; Matthew Malachowski, Pharm. D., MHA
0.75 program credits
- J.A. Randy Englert, MD, FACC
- Matthew Malachowski, Pharm. D., MHA
0.75 program credits
MinuteCE®
ASCVD Playbook | Closing the Gaps, One Inning at a Time
J.A. Randy Englert, MD, FACC; Matthew Malachowski, Pharm. D., MHA
0.75 credits 6 episodes
- J.A. Randy Englert, MD, FACC
- Matthew Malachowski, Pharm. D., MHA
0.75 credits 6 episodes
Crossing Home Plate – Building a Winning Team Culture
Crossing Home Plate – Building a Winning Team Culture
MinuteCE®
Crossing Home Plate – Building a Winning Team Culture
J.A. Randy Englert, MD, FACC; Matthew Malachowski, Pharm. D., MHA
0.75 program credits
- J.A. Randy Englert, MD, FACC
- Matthew Malachowski, Pharm. D., MHA
0.75 program credits
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
Cardiology
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
Florian Rader, MD
- Florian Rader, MD
SCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
SCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Cardiology
SCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Joseph Rossano, MD
- Joseph Rossano, MD
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
Cardiology
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
Joseph Rossano, MD
- Joseph Rossano, MD
When ß-Blockers Fall Short in oHCM: Time for a New Approach?
When ß-Blockers Fall Short in oHCM: Time for a New Approach?
MinuteCE®
When ß-Blockers Fall Short in oHCM: Time for a New Approach?
Ahmad Masri, MD, MS; Anjali Tiku Owens, MD
1.00 program credit
- Ahmad Masri, MD, MS
- Anjali Tiku Owens, MD
1.00 program credit
From Beta-Blockers to Myosin Inhibitors: Initial Decision-Making in Obstructive HCM
From Beta-Blockers to Myosin Inhibitors: Initial Decision-Making in Obstructive HCM
MinuteCE®
From Beta-Blockers to Myosin Inhibitors: Initial Decision-Making in Obstructive HCM
Ahmad Masri, MD, MS; Anjali Tiku Owens, MD
1.00 program credit
- Ahmad Masri, MD, MS
- Anjali Tiku Owens, MD
1.00 program credit
Molecular Precision: How Myosin Inhibitors Redefine Control
Molecular Precision: How Myosin Inhibitors Redefine Control
MinuteCE®
Molecular Precision: How Myosin Inhibitors Redefine Control
Ahmad Masri, MD, MS; Anjali Tiku Owens, MD
1.00 program credit
- Ahmad Masri, MD, MS
- Anjali Tiku Owens, MD
1.00 program credit
Redefining oHCM Care: Efficacy and Safety of Myosin Inhibitors
Redefining oHCM Care: Efficacy and Safety of Myosin Inhibitors
MinuteCE®
Redefining oHCM Care: Efficacy and Safety of Myosin Inhibitors
Michael Nassif, MD, MSc; Anjali Tiku Owens, MD
1.00 program credit
- Michael Nassif, MD, MSc
- Anjali Tiku Owens, MD
1.00 program credit
From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
MinuteCE®
From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
Michael Nassif, MD, MSc; Anjali Tiku Owens, MD
1.00 program credit
- Michael Nassif, MD, MSc
- Anjali Tiku Owens, MD
1.00 program credit

Prev
1
2
3
…
8
9
Next

1/6